FDA Approved: TYRUKO — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for TYRUKO (natalizumab-sztn) from Sandoz Inc. TYRUKO is a biosimilar to natalizumab (Tysabri) indicated for multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• TYRUKO (natalizumab-sztn)

Snippet

SUPPL AP for TYRUKO (NATALIZUMAB-SZTN)